Literature DB >> 27065851

Comparison of Efficacy of Two Different Topical 0.05% Cyclosporine A Formulations in the Treatment of Adenoviral Keratoconjunctivitis-Related Subepithelial Infiltrates.

Betül N Bayraktutar1, Ömur Ö Uçakhan1.   

Abstract

Subepithelial infiltrates secondary to adenoviral keratoconjunctivitis may persist for years and cause blurred vision, halos, glare, and photophobia. These infiltrates arise from immune reaction against the virus, and few studies have reported topical cyclosporine A to be effective in the treatment of subepithelial infiltrates. Herein, we describe a patient with adenoviral keratoconjunctivitis-related subepithelial infiltrates who did not respond to treatment with a new topical cyclosporine A emulsion prepared with castor oil (Depores 0.05%; Deva İlaç, Kocaeli, Turkey), while the FDA-approved nanoemulsion formulation provided improvement in symptoms and reduced the inflammatory reaction (Restasis 0.05%; Allergan, Irvine, Calif., USA).

Entities:  

Keywords:  Adenoviral keratoconjunctivitis; Cyclosporine A; Subepithelial infiltrates

Year:  2016        PMID: 27065851      PMCID: PMC4821138          DOI: 10.1159/000444784

Source DB:  PubMed          Journal:  Case Rep Ophthalmol        ISSN: 1663-2699


  8 in total

1.  Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis.

Authors:  Eliya Levinger; Alana Slomovic; Wiwan Sansanayudh; Irit Bahar; Allan R Slomovic
Journal:  Cornea       Date:  2010-06       Impact factor: 2.651

2.  Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs.

Authors:  A A Acheampong; M Shackleton; D D Tang-Liu; S Ding; M E Stern; R Decker
Journal:  Curr Eye Res       Date:  1999-02       Impact factor: 2.424

Review 3.  Cyclosporine A delivery to the eye: a pharmaceutical challenge.

Authors:  F Lallemand; O Felt-Baeyens; K Besseghir; F Behar-Cohen; R Gurny
Journal:  Eur J Pharm Biopharm       Date:  2003-11       Impact factor: 5.571

4.  In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.

Authors:  M Rodriguez-Aller; B Kaufmann; D Guillarme; C Stella; P Furrer; S Rudaz; I El Zaoui; F Valamanesh; C Di Tommaso; F Behar-Cohen; J-L Veuthey; R Gurny
Journal:  Eur J Pharm Biopharm       Date:  2011-12-03       Impact factor: 5.571

5.  Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis.

Authors:  Bennie H Jeng; Douglas S Holsclaw
Journal:  Cornea       Date:  2011-09       Impact factor: 2.651

6.  Corneal histology after epidemic keratoconjunctivitis.

Authors:  O E Lund; F H Stefani
Journal:  Arch Ophthalmol       Date:  1978-11

Review 7.  Adenoviral keratoconjunctivitis.

Authors:  Vishal Jhanji; Tommy C Y Chan; Emmy Y M Li; Kanika Agarwal; Rasik B Vajpayee
Journal:  Surv Ophthalmol       Date:  2015-05-05       Impact factor: 6.048

8.  Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis.

Authors:  Seydi Okumus; Erol Coskun; Mehmet Gurkan Tatar; Erdal Kaydu; Ramazan Yayuspayi; Aysegul Comez; Ibrahim Erbagci; Bulent Gurler
Journal:  BMC Ophthalmol       Date:  2012-08-18       Impact factor: 2.209

  8 in total
  1 in total

Review 1.  Topical tacrolimus in anterior segment inflammatory disorders.

Authors:  Samir S Shoughy
Journal:  Eye Vis (Lond)       Date:  2017-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.